OPNT CEO Discusses The State Of The Opioid Crisis

Schwab Network

English - April 19, 2021 18:00 - 8 minutes - 55 MB - ★★★★★ - 23 ratings
News Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Outlook For Small-Cap Value Stocks In 2021

Next Episode: Travel Sector Notes

The CEO of Opiant Pharmaceuticals (OPNT), Dr. Roger Crystal, says that the company develops treatments for substance use, as well as addictive and eating disorders. Their breakthrough naloxone nasal spray treatments are FDA approved for treatment of opioid overdose. The stock is up 32% in 2021.